tisagenlecleucel – Page 2

Comparison of safety management costs across chimeric antigen receptor (CAR) T cell therapies in relapsed or refractory large B-cell lymphoma

Log In with AHPRA Professional Number Login Some areas of the CAR-T Central site may only be accessed by health care professionals. You are required to enter your full AHPRA […]

CD19 CAR T-cell therapy for relapsed/refractory diffuse large B-cell lymphoma – the Munich real life experience

Log In with AHPRA Professional Number Login Some areas of the CAR-T Central site may only be accessed by health care professionals. You are required to enter your full AHPRA […]

Outcome of high-grade lymphoma patients treated with CD19 CAR-T – updated real-world experience in the UK

Log In with AHPRA Professional Number Login Some areas of the CAR-T Central site may only be accessed by health care professionals. You are required to enter your full AHPRA […]

Cost effectiveness of axicabtagene ciloleucel (axi-cel) and tisagenlecleucel (tisa-cel) for adult patients with relapsed or refractory large B-cell lymphoma (rr lbcl) in the US

Log In with AHPRA Professional Number Login Some areas of the CAR-T Central site may only be accessed by health care professionals. You are required to enter your full AHPRA […]

High-grade neurological toxicity following CD19 CAR-T therapy: outcomes from a single centre experience

Log In with AHPRA Professional Number Login Some areas of the CAR-T Central site may only be accessed by health care professionals. You are required to enter your full AHPRA […]

Outcomes of anti-CD19 CAR-T cell therapy for transformed non follicular lymphoma

Log In with AHPRA Professional Number Login Some areas of the CAR-T Central site may only be accessed by health care professionals. You are required to enter your full AHPRA […]

Real-world results of anti-CD19 CAR-T cells use for patients with relapsed/refractory large B-cell lymphoma in Lyon Sud hospital

Log In with AHPRA Professional Number Login Some areas of the CAR-T Central site may only be accessed by health care professionals. You are required to enter your full AHPRA […]

A Phase II, Open-Label, Single Arm Trial to Assess the Efficacy and Safety of the Combination of Tisagenlecleucel and Ibrutinib in Mantle Cell Lymphoma (TARMAC)

This poster describes a clinical trial of tisagenlecleucel + ibrutinib that is currently recruiting in Australia. The trial allows very early recruitment of patients with MCL+genomic risk factors, or recruitment […]